Differential Sensitization to Ambulation-Increasing Effect of Methamphetamine after Repeated Administration to Mice in Activity Cages of Different Sizes

Hirabayasi, Makizo; Saito, Takashi; Tadokoro, Sakutaro

doi:10.1254/jjp.57.91

Cited by 10 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the slip-down is considered to be a result of increase of ambulation, the present findings agree with a previous report [3]. However, Hirabayashi et al reported that the ambulation-increasing effect of MAP was significantly enhanced on platforms with diameters greater than 15 cm [1]. This may suggest that the slipdown has a behavioral meaning different from increase of the ambulation.…”

supporting

confidence: 91%

Slip-down from a Raised Platform: Another Behavior of Slc:ddY Mice Treated with Methamphetamine

Masuda

Matsuda

2004

Exp. Anim.

View full text Add to dashboard Cite

Slip-down behavior from a raised platform of Slc:ddY mice was examined. Mice intraperioneally injected with 1 or 1.5 mg/kg of methamphetamine (MAP) slipped down from a raised platform of 10 cm diameter and 20 cm height within 5 min, 20 min after the injection. After pretreatment five times with 1 mg/kg MAP at intervals of 3 days, the slipdown was induced after injection of 0.5, 1 or 1.5 mg/kg MAP, but after pretreatment ten times with 1 mg/kg MAP at intervals of 3 days the behavior was not recognized at the same doses. These phenomena were like reverse-tolerance and tolerance. The situational change of the MAP treatments, placement on the platform after each pretreatment, did not affect the phenomena. The present findings strongly suggest that the slip-down is a behavior affected by the dose and number of administration of MAP, but not by the treatment situation. Key words: Slc:ddY mouse, methamphetamine, slip-down from a raised platform chased from Dainihon Seiyaku Co. Osaka, Japan. Physiological saline (PS), 200 µl , as a control or 0.5, 1 or 1.5 mg/kg of MAP were intraperitoneally respectively injected to one of four groups of 5 mice. Twenty minutes after the injection, each of these mice was placed on a raised platform (10 cm diameter, 20 cm height) and their behavior was investigated for 5 min. All of the mice moved about on the platform: forwards, backwards and changing body direction. Mice injected with PS or 0.5 mg/kg of MAP stopped at the edge of the platform, but mice injected with the 1 or 1.5 mg/kg MAP could not stop themselves at the edge and slippeddown from the platform within 5 min. None of the mice showed stereotypical behavior, sniffing and headbobbing, induced by MAP [4].

show abstract

supporting

confidence: 91%

Slip-down from a Raised Platform: Another Behavior of Slc:ddY Mice Treated with Methamphetamine

Masuda

Matsuda

2004

Exp. Anim.

View full text Add to dashboard Cite

show abstract

“…It could be argued, for example, that the ability of SCH 23390 to block the effects of repeated quinpirole or apomorphine treatments on subsequent sensitivity to apomorphine is due to a general depression of locomotor activity rather than to a specific blockade of dopamine D1 receptors (cf Hirabayasi et al 1991). Although this explanation cannot be exclusively ruled out on the basis of the present results, there are several arguments against this view.…”

Section: Discussionmentioning

confidence: 65%

Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine

1993

View full text Add to dashboard Cite

In three experiments, male Wistar rats (250-350 g) were injected (SC) daily with the D1-type dopamine receptor agonist, SKF 38393 (0.0, 4.0, 8.0, or 16.0 mg/kg), the D2-type dopamine receptor agonist, quinpirole (0.0, 0.3, or 3.0 mg/kg), and/or the D1-type dopamine receptor antagonist, SCH 23390 (0.0 or 0.5 mg/kg) for 8-10 days. After each daily injection, the rats were tested for locomotor activity in photocell arenas for 20 min. Following this subchronic pretreatment, all rats were challenged with the mixed dopamine receptor agonist apomorphine (1.0 mg/kg, SC) and tested for locomotor activity. SKF 38393 treatments produced a dose-dependent decrease in locomotor activity which did not significantly change across days. Quinpirole also depressed locomotor activity when first injected, but this quinpirole-induced inhibition of activity progressively decreased across days. When subsequently challenged with apomorphine, rats in both the SKF 38393 and the quinpirole pretreatment groups displayed greater locomotor activity than rats pretreated with only vehicle. Although SCH 23390 pretreatments did not affect subsequent sensitivity to apomorphine, SCH 23390 completely blocked the effect of quinpirole. These results suggest that although repeated D1 receptor stimulation may be sufficient to induce behavioral sensitization to apomorphine, D2 receptor stimulation also contributes to the effect.

show abstract

“…Figure 1(I) shows the protocol used for inducing the development and expression of locomotor sensitization with METH in male C3H/HeN (WT, MT 1 KO, MT 2 KO, MT 1 /MT 2 KO) mice during the light (ZT 5–7) and dark phases (ZT 19–21). VEH or METH pretreatments and challenge after four full days of abstinence were administered in a novel environment that is, cylindrical arenas 20 cm in diameter [25]. Locomotor activity was recorded continuously for 2 hr after treatment to assess the temporal development of sensitization by METH.…”

Section: Resultsmentioning

confidence: 99%

Genetic deletion of MT₁and MT₂melatonin receptors differentially abrogates the development and expression of methamphetamine‐induced locomotor sensitization during the day and the night in C3H/HeN mice

Hutchinson¹,

Hudson

Dubocovich³

2012

Journal of Pineal Research

View full text Add to dashboard Cite

This study explored the role of the melatonin receptors in methamphetamine (METH)-induced locomotor sensitization during the light and dark phases in C3H/HeN mice with genetic deletion of theMT1 and/or MT2 melatonin receptors. Six daily treatments with METH (1.2 mg/kg, i.p.) in a novel environment during the light phase led to the development of locomotor sensitization in wild-type (WT), MT1KO and MT2KO mice. Following four full days of abstinence, METH challenge (1.2 mg/kg, i.p.) triggered the expression of locomotor sensitization in METH-pretreated but not in vehicle (VEH)-pretreated mice. In MT1/MT2KO mice, the development of sensitization during the light phase was significantly reduced and the expression of sensitization was completely abrogated upon METH challenge. During the dark phase the development of locomotor sensitization in METH-pretreated WT, MT1KO and MT2KO mice was statistically different from VEH-treated controls. However, WT and MT2KO, but not MT1KO mice receiving repeated VEH pretreatments during the dark phase expressed a sensitized response to METH challenge that is of an identical magnitude to that observed upon 6 days of METH pretreatment. We conclude that exposure to a novel environment during the dark phase, but not during the light phase, facilitated the expression of sensitization to a METH challenge in a manner dependent on MT1 melatonin receptor activation by endogenous melatonin. We suggest that MT1 and MT2 melatonin receptors are potential targets for pharmacotherapeutic intervention in METH abusers.

show abstract

Differential Sensitization to Ambulation-Increasing Effect of Methamphetamine after Repeated Administration to Mice in Activity Cages of Different Sizes

Cited by 10 publications

References 19 publications

Slip-down from a Raised Platform: Another Behavior of Slc:ddY Mice Treated with Methamphetamine

Slip-down from a Raised Platform: Another Behavior of Slc:ddY Mice Treated with Methamphetamine

Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine

Genetic deletion of MT₁and MT₂melatonin receptors differentially abrogates the development and expression of methamphetamine‐induced locomotor sensitization during the day and the night in C3H/HeN mice

Contact Info

Product

Resources

About

Differential Sensitization to Ambulation-Increasing Effect of Methamphetamine after Repeated Administration to Mice in Activity Cages of Different Sizes

Cited by 10 publications

References 19 publications

Slip-down from a Raised Platform: Another Behavior of Slc:ddY Mice Treated with Methamphetamine

Slip-down from a Raised Platform: Another Behavior of Slc:ddY Mice Treated with Methamphetamine

Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine

Genetic deletion of MT1and MT2melatonin receptors differentially abrogates the development and expression of methamphetamine‐induced locomotor sensitization during the day and the night in C3H/HeN mice

Contact Info

Product

Resources

About

Genetic deletion of MT₁and MT₂melatonin receptors differentially abrogates the development and expression of methamphetamine‐induced locomotor sensitization during the day and the night in C3H/HeN mice